GW Pharma's Sativex Performs Well in MS Spasticity Study
LONDON – GW Pharma plc delivered positive results in a UK Phase III postmarketing study of Sativex, which will provide ballast for the launch of the cannabis-based product as a treatment for spasticity caused by multiple sclerosis in national markets across Europe and the Middle East.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter